T
Thomas C. Merigan
Researcher at Stanford University
Publications - 515
Citations - 34283
Thomas C. Merigan is an academic researcher from Stanford University. The author has contributed to research in topics: Interferon & Virus. The author has an hindex of 98, co-authored 514 publications receiving 33941 citations. Previous affiliations of Thomas C. Merigan include University of Arizona & Rockefeller Institute of Government.
Papers
More filters
Journal ArticleDOI
Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection: A Controlled Trial in Persons with Fewer Than 500 CD4-Positive Cells per Cubic Millimeter
Paul A. Volberding,Stephen W. Lagakos,Matthew A. Koch,David K. Booth,Carla Pettinelli,Maureen Myers,Henry H. Balfour,Richard C. Reichman,John Bartlett,Martin S. Hirsch,Robert L. Murphy,W. David Hardy,Ruy Soeiro,Margaret A. Fischl,John G. Bartlett,Thomas C. Merigan,Newton E. Hyslop,Douglas D. Richman,Fred T. Valentine,Lawrence Corey +19 more
TL;DR: Zidovudine is safe and effective in persons with asymptomatic HIV infection and fewer than 500 CD4+ cells per cubic millimeter and additional study will be required to determine whether such treatment will ultimately improve survival for persons infected with HIV.
Journal ArticleDOI
A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter
Scott M. Hammer,David Katzenstein,Michael Hughes,Holly Gundacker,Robert T. Schooley,Richard Haubrich,W. Keith Henry,Michael M. Lederman,John P. Phair,Manette T. Niu,Martin S. Hirsch,Thomas C. Merigan +11 more
TL;DR: In this article, a double-blind study evaluated treatment with either a single nucleoside or two nucleosides in adults infected with human immunodeficiency virus type 1 (HIV-1) whose CD4 cell counts were from 200 to 500 per cubic millimeter.
Journal ArticleDOI
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
Ann C. Collier,Robert W. Coombs,David A. Schoenfeld,Roland L. Bassett,Joseph Timpone,Alice Baruch,Michelle Jones,Karen Facey,Caroline C. Whitacre,Vincent McAuliffe,Harvey M. Friedman,Thomas C. Merigan,Richard C. Reichman,Carol J. Hooper,Lawrence Corey +14 more
TL;DR: This drug combination reduced HIV-1 replication, increased CD4+ cell counts, and decreased levels of activation markers in serum more than did treatment with zidovudine and either saquinavir or zalcitabine.
Journal ArticleDOI
Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arrays
Michael J. Kozal,Nila Shah,Naiping Shen,Robert Yang,Raymond V. Fucini,Thomas C. Merigan,Douglas D. Richman,Douglas D. Richman,Don Morris,Earl Hubbell,Mark S. Chee,Thomas R. Gingeras +11 more
TL;DR: In the first clinical application of high–density oligonucleotide arraysequencing, the sequences of 167 viral isolates from 102 patients have been determined and the DNA sequence of USA HIV–1 clade B proteases was found to be extremely variable.
Journal Article
Recombinant interferon-gamma increases HLA-DR synthesis and expression.
TL;DR: It is reported here that recombinant interferon-gamma (IFN-Gamma) increases the synthesis and expression of the HLA-DR (la-like) antigens as well as beta 2-microglobulin (beta 2-m), a low m.w. subunit of HLA, on human melanoma cells.